Skip to main content
AmigoFish

Sentiment at BIO soars as FDA resets, dealmaking evolves; Amgen’s Tavneos in hot water

From BioSpace · · 22 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

The vibe at BIO 2026 in San Diego last week was overwhelmingly positive, with attendees observing noticeable changes at the FDA and an uptick in dealmaking and IPOs. Plus, a top medical journal this week retracted a pivotal study for Amgen’s rare disease drug Tavneos, which has been in the FDA’s crosshairs since January.

Back to BioSpace · Report a problem